Altimmune, Inc. (ALT) Research

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Market snapshot

Symbol
ALT
Price
$2.70
Day change
+2.27%
Market cap
$238.3M
P/E ratio
-3.69x
52-week range
2.56-7.73
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$11.25

Peer companies

  • AC Immune S.A. (ACIU)
  • Amarin Corporation plc (AMRN)
  • Annexon, Inc. (ANNX)
  • Alto Neuroscience, Inc. (ANRO)
  • Aura Biosciences, Inc. (AURA)
  • DBV Technologies S.A. (DBVT)
  • enGene Holdings Inc. (ENGN)
  • Korro Bio, Inc. (KRRO)

Recent insider activity

  • Lawver Teri L — A-Award (48800 shares) on 2026-05-01
  • Sohn Catherine A. — A-Award (48800 shares) on 2026-05-01
  • Jorkasky Diane — A-Award (48800 shares) on 2026-05-01
  • Schafer Klaus — A-Award (48800 shares) on 2026-05-01
  • Pisano Wayne — A-Award (48800 shares) on 2026-05-01

Open Altimmune, Inc. (ALT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.